{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:02:08Z","timestamp":1773032528112,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vedolizumab, a gut\u2010selective \u03b14\u03b27 integrin antagonist, is widely used for the treatment of ulcerative colitis (UC) and is generally considered to have a favorable systemic infection safety profile. During routine clinical practice, we observed an unexpected clustering of urinary tract infections (UTIs) among patients initiating vedolizumab in an Iranian cohort, prompting further evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single\u2010center, observational case series included 15 adult patients with moderate\u2010to\u2010severe UC treated with vedolizumab and followed prospectively for 12\u2009weeks for the occurrence of UTIs. A contemporaneous comparator cohort of 30 UC patients treated with infliximab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915) or tofacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915) was followed over the same period. The primary outcome was symptomatic, culture\u2010proven UTI, defined as &gt;\u200910\n                      <jats:sup>5<\/jats:sup>\n                      CFU\/mL of a single uropathogen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients treated with vedolizumab demonstrated significant clinical improvement, with a mean Mayo score reduction from 8.2 to 3.5 during follow\u2010up. An unexpectedly high number of early symptomatic UTIs was observed in the vedolizumab group, including cases caused by non\u2010typhoidal Salmonella species, whereas no UTIs were detected in the small comparator cohorts. Given the limited sample size and observational design, reliable estimation of relative risk was not possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small, single\u2010center cohort, an unusual clustering of early symptomatic UTIs was observed among patients initiating vedolizumab. These findings are observational and hypothesis\u2010generating, and no causal relationship can be inferred. They highlight the importance of real\u2010world pharmacovigilance and the need for larger, multicenter studies to clarify whether such infection patterns reflect contextual clustering or reproducible safety signals influenced by regional epidemiological factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jgh3.70355","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:05:21Z","timestamp":1772971521000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Unusual Cluster of Urinary Tract Infections, Including Salmonella spp., in an Iranian Ulcerative Colitis Cohort Treated With Vedolizumab: A Case Series and Comparative Analysis"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4247-3533","authenticated-orcid":false,"given":"Yousef","family":"VatanParast","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Shafa Hospital  Ahvaz Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211093"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023119"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2031"},{"issue":"3","key":"e_1_2_12_5_1","first-page":"611","article-title":"Real\u2010World Safety of Vedolizumab in Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study","volume":"18","author":"Dulai P. S.","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjac045"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI\u20100002\u20102012"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"issue":"3","key":"e_1_2_12_9_1","first-page":"e20","article-title":"Non\u2010Typhoidal Salmonella Urinary Tract Infection in An Immunocompetent Adult: Case Report and Review of the Literature","volume":"50","author":"Tenaillon O.","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.12.005"},{"issue":"10","key":"e_1_2_12_11_1","first-page":"2239","article-title":"Western Dietary Pattern is Associated With Increased Risk of Inflammatory Bowel Disease: Results From a Large Prospective Cohort Study","volume":"20","author":"Peters V.","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.135"}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.70355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jgh3.70355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.70355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:10:52Z","timestamp":1773029452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.70355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jgh3.70355"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.70355","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"value":"2397-9070","type":"print"},{"value":"2397-9070","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70355"}}